PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21034736-7	2011	Montelukast treatment also decreased mRNA levels of IL-6, IL-10, IL-13, and TGF-beta1, all of which were elevated in fibrotic lungs.	montelukast	0-11	transforming growth factor, beta 1	Mus musculus	76-85	
24126112-9	2013	In conclusion, the administration of montelukast reduced airway inflammation and pulmonary fibrosis by reducing the release of Th2 cytokines and the expression of VEGF, TGF-beta1/Smad3 in the lung tissue.	montelukast	37-48	transforming growth factor, beta 1	Mus musculus	169-178	
21034736-11	2011	These results suggest that montelukast exhibits its beneficial effects by inhibiting the overexpression of IL-6, IL-10, IL-13, and TGF-beta1 and by modulating the homeostatic balance between the cysteinyl-leukotriene type 1 and type 2 receptors.	montelukast	27-38	transforming growth factor, beta 1	Mus musculus	131-140	
17397875-7	2007	The results of this study show that montelukast inhibits the inflammatory process and development of bleomycin-induced pulmonary fibrosis in mice and that these effects may be associated with a decrease in TGFbeta expression.	montelukast	36-47	transforming growth factor, beta 1	Mus musculus	206-213